Patient Perspectives on the Introduction of Subsequent Entry Biologics in Canada.

被引：0
|
作者：
Sekhon, Suneet [1 ]
Rai, Raman [1 ]
McClory, Debbie [2 ]
Whiskin, Carolyn [2 ]
Deamude, Melissa [2 ]
Mech, Cynthia [2 ]
Vanstone, Lauri [2 ]
Shah, Alpesh [3 ]
Lau, Arthur N. [1 ]
Bensen, William [1 ]
机构：
[1] McMaster Univ, Div Rheumatol, Hamilton, ON, Canada
[2] Dr Bensens Rheumatol Clin, Rheumatol Hlth Team, Hamilton, ON, Canada
[3] Univ Western Ontario, London, ON, Canada
来源：
ARTHRITIS & RHEUMATOLOGY | 2014年 / 66卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1507
引用
收藏
页码：S663 / S663
页数：1
相关论文
共 50 条
  • [1] Survey of Patient Perspectives on the Introduction of Subsequent Entry Biologics in Canada
    Sekhon, Suneet
    Rai, Raman
    Lau, Arthur
    Vanstone, Lauri
    McClory, Debbie
    Whiskin, Carolyn
    Deamude, Melissa
    Mech, Cynthia
    Shah, Alpesh
    Bensen, William
    [J]. JOURNAL OF RHEUMATOLOGY, 2015, 42 (07) : 1336 - 1337
  • [2] Current state of subsequent entry biologics (biosimilars) in Canada: a view from regulatory, reimbursement, clinician, and patient perspectives
    Siu, Eric C. K.
    Wyatt, George
    [J]. GABI JOURNAL-GENERICS AND BIOSIMILARS INITIATIVE JOURNAL, 2016, 5 (03): : 105 - 113
  • [3] Subsequent entry biologics/biosimilars: a viewpoint from Canada
    Anthony S. Russell
    Vandana Ahluwalla
    Cheryl Barnabe
    Shahin Jamal
    Robert C. Offer
    Wojciech P. Olszynski
    Kam Shojania
    Boulos Haraoui
    [J]. Clinical Rheumatology, 2012, 31 : 1289 - 1292
  • [4] Subsequent entry biologics/biosimilars: a viewpoint from Canada
    Russell, Anthony S.
    Ahluwalla, Vandana
    Barnabe, Cheryl
    Jamal, Shahin
    Offer, Robert C.
    Olszynski, Wojciech P.
    Shojania, Kam
    Haraoui, Boulos
    [J]. CLINICAL RHEUMATOLOGY, 2012, 31 (09) : 1289 - 1292
  • [5] Subsequent Entry Biologics in Canada: Current State of the Science
    Endrenyi, Laszlo
    Jamali, Fakhreddin
    Loebenberg, Raimar
    [J]. JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES, 2015, 18 (02): : 177 - 183
  • [6] Preparing for Subsequent Entry Biologics in Dermatology and Rheumatology in Canada
    Papp, Kim
    Bourcier, Marc
    Ho, Vincent
    Burke, Karen
    Haraoui, Boulos
    [J]. JOURNAL OF CUTANEOUS MEDICINE AND SURGERY, 2013, 17 (05) : 340 - 346
  • [7] Canadian patient and caregiver perspectives on subsequent entry biologics/biosimilars for inflammatory bowel disease
    Attara, G.
    Bailey, R.
    Bressler, B.
    Marshall, J.
    Panaccione, R.
    Aumais, G.
    [J]. JOURNAL OF CROHNS & COLITIS, 2016, 10 : S319 - S319
  • [8] Canadian Patient and Caregiver Perspectives on Subsequent Entry Biologics/Biosimilars for Inflammatory Bowel Disease
    Attara, Gail
    Bressler, Brian
    Bailey, Robert
    Marshall, John. K.
    Panaccione, Remo
    Aumais, Guy
    [J]. GASTROENTEROLOGY, 2016, 150 (04) : S443 - S444
  • [9] An introduction to biologics and biosimilars. Part II: Subsequent entry biologics: Biosame or biodifferent?
    Revers, Leigh
    Furczon, Eva
    [J]. CANADIAN PHARMACISTS JOURNAL, 2010, 143 (04) : 184 - 191
  • [10] Subsequent entry biologics (biosimilars) in Canada: approaches to interchangeability and the extrapolation of indications and uses
    Klein, Agnes V.
    Wang, Jian
    Bedford, Patrick
    [J]. GABI JOURNAL-GENERICS AND BIOSIMILARS INITIATIVE JOURNAL, 2014, 3 (03): : 150 - 154
12345